News and reporting on cell-free DNA testing.
During a conference call, company executives also discussed results from the SMART NIPT trial and their outlook for Natera's three businesses.
The company recently announced a deal with personalized ctDNA testing firm Natera and will now follow that with the launch of its own MRD product this year.
The company doesn’t expect significant revenue from the test this year, but executives said that they are already seeing positive reception trends.
The company reported $112.4 million in revenues compared to $83.2 million in Q4 2019, beating the average Wall Street estimate of $106.6 million.
The firm expects to release an expanded liquid biopsy panel this year to help pharmaceutical partners perform blood-based biomarker discovery work.
